Get started
Author

Edward C. Li

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives
2011 · Andrew D. Zelenetz, Islah Ahmed, et al. · Journal of the National Comprehensive Cancer Network · 141
PDF
Zoledronic acid: A new parenteral bisphosphonate
2003 · Edward C. Li, Lisa E. Davis · Clinical Therapeutics · 107
National trends in prescription drug expenditures and projections for 2016
2016 · Glen T. Schumock, Edward C. Li, et al. · American Journal of Health-System Pharmacy · 102
Drug‐Induced QT‐Interval Prolongation: Considerations for Clinicians
2010 · Edward C. Li, John S. Esterly, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 72
National trends in prescription drug expenditures and projections for 2014
2014 · Glen T. Schumock, Edward C. Li, et al. · American Journal of Health-System Pharmacy · 69
National trends in prescription drug expenditures and projections for 2017
2017 · Glen T. Schumock, Edward C. Li, et al. · American Journal of Health-System Pharmacy · 58
National trends in prescription drug expenditures and projections for 2015
2015 · Glen T. Schumock, Edward C. Li, et al. · American Journal of Health-System Pharmacy · 39
NCCN Task Force Report: Specialty Pharmacy
2010 · Rowena N. Schwartz, Kirby J. Eng, et al. · Journal of the National Comprehensive Cancer Network · 39
PDF
National trends in prescription drug expenditures and projections for 2018
2018 · Glen T. Schumock, JoAnn Stubbings, et al. · American Journal of Health-System Pharmacy · 32
Considerations in the early development of biosimilar products
2015 · Edward C. Li, Richat Abbas, et al. · Drug Discovery Today · 30
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders
2010 · Philip E. Johnson, George Dahlman, et al. · Journal of the National Comprehensive Cancer Network · 22
PDF
Spending on Antineoplastic Agents in the United States, 2011 to 2016
2018 · Samuel J. Hong, Edward C. Li, et al. · Journal of Oncology Practice · 20
Accuracy of annual prescription drug expenditure forecasts inAJHP
2015 · Patricia L. Hartke, Lee C. Vermeulen, et al. · American Journal of Health-System Pharmacy · 7
Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology
2010 · Edward C. Li, Jessica DeMartino · Journal of the National Comprehensive Cancer Network · 6
Insights and Perspectives in the Clinical and Operational Management of Cancer-Related Anemia
2010 · Jennifer M. Hinkel, Edward C. Li, et al. · Journal of the National Comprehensive Cancer Network · 4
PDF
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US
2024 · Jeanine A. Flanigan, Marie Yasuda, et al. · Supportive Care in Cancer · 3
A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
2019 · Gary H. Lyman, Dylan Mezzio, et al. · Journal of Clinical Oncology · 3
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
2020 · Edward C. Li, Dylan Mezzio, et al. · Journal of Clinical Oncology · 2
Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia.
2021 · Edward C. Li, Kimberley J. Campbell, et al. · Journal of Clinical Oncology · 1
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.
2020 · Edward C. Li, Dylan Mezzio, et al. · Journal of Clinical Oncology · 1
Spending on antineoplastic agents in the United States: 2011-2016.
2017 · Edward C. Li, Glen Schumock, et al. · Journal of Clinical Oncology · 1
The “Big 6 Spotlight”: Baseline assessment and implementation of a process to systematically collect critical oncology data elements for quality improvement and research.
2012 · Edward C. Li, Steven L. D’Amato, et al. · Journal of Clinical Oncology · 1
A Quick REMS Update and a Clinical Focus
2011 · Edward C. Li · Journal of the National Comprehensive Cancer Network · 1
PDF
Exploring Pharmacy and Drug Policy Concerns
2010 · Edward C. Li · Journal of the National Comprehensive Cancer Network · 1
PDF
Chemotherapy-induced febrile neutropenia (FN) in the US: healthcare resource utilization (HCRU) and costs
2023 · Jeanine A. Flanigan, Marie Yasuda, et al. · Research Square
Works count: 35
Citation count: 762
H-index: 12
I10-index: 12
Year
Topic
Type